VYNE Therapeutics Reports Second Quarter 2022 Financial Results

Bridgewater, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) —

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30, 2022.

During the announcement, VYNE’s CEO stated, “We believe our BET inhibitor platform holds unique and significant potential in the treatment of immuno-inflammatory conditions. The second quarter financial results demonstrate the progress we are making towards our goal of providing novel therapies to improve patient outcomes.”

Financial Results Overview

For the second quarter of 2022, VYNE reported a net loss of $10.5 million, compared to a net loss of $12.1 million for the same period in 2021. The company’s total revenue for the quarter was $5.8 million, driven by sales of its flagship immuno-inflammatory drug.

Additionally, VYNE ended the quarter with $50 million in cash and cash equivalents, positioning the company well for future growth and development of its pipeline of therapies.

Impact on Individuals

For individuals suffering from immuno-inflammatory conditions, the financial results announced by VYNE Therapeutics are promising. The continued investment in innovative therapies demonstrates a commitment to improving patient outcomes and providing new treatment options for those in need.

Potential patients may benefit from the development of VYNE’s BET inhibitor platform, which could offer a novel approach to managing their condition and improving their quality of life.

Global Implications

On a global scale, the advancements made by VYNE in the field of immuno-inflammatory therapies have the potential to impact the healthcare industry and research community. The development of proprietary and differentiated treatments could lead to new standards of care and better outcomes for patients around the world.

By investing in innovative therapies and pushing the boundaries of scientific discovery, VYNE is contributing to the collective effort to address unmet medical needs and improve health outcomes on a global scale.

Conclusion

The financial results reported by VYNE Therapeutics for the second quarter of 2022 showcase the company’s commitment to advancing novel therapies for immuno-inflammatory conditions. With a focus on innovation and patient outcomes, VYNE’s BET inhibitor platform holds significant promise for individuals in need of new treatment options. The global implications of VYNE’s work underscore the importance of continued investment in research and development to drive progress in healthcare and improve outcomes for patients worldwide.